Table 1.
Baseline characteristics of evaluable participants (N = 14)
| Characteristic | N (%) or median (range) |
|---|---|
| Sex | |
| Female | 14 (100%) |
| Male | 0 (0%) |
| Age (years) | 58.5 (50.8–68.3) |
| BMI (kg/m2) | 27.4 (23.9–28.5) |
| WHO performance status | |
| 0 | 12 (86%) |
| 1 | 2 (14%) |
| Ethnic origin | |
| Caucasian | 12 (86%) |
| Afro-Caribbean | 2 (14%) |
| CYP2D6 phenotype | |
| EM | 11 (79%) |
| IM | 3 (21%) |
| Biochemistry | |
| AST (U/L) | 21 (17.8–27.0) |
| ALT (U/L) | 15 (11.8–21.0) |
| ALP (U/L) | 53.5 (43–67) |
| GGT (U/L) | 21 (16.5–29.5) |
| Total bilirubin (µmol/L) | 6 (5.3–8.5) |
| Albumin (g/L) | 36 (35–37) |
| LD (U/L) | 189 (181.5–196.5) |
| Hb (mmol/L) | 8.1 (7.7–8.3) |
| Creatinine (µmol/L) | 76.5 (71.8–87.3) |
| Previous treatment | |
| Surgery | 14 (100%) |
| Radiotherapy | 9 (64%) |
| Chemotherapy | 3 (21%) |
| Tamoxifen dose | |
| 20 mg | 13 (93%) |
| 40 mg | 1 (7%) |
| Duration of adjuvant tamoxifen use (months) | 11.8 (6.0–12.9) |
BMI body mass index, EM extensive metabolism, IM intermediate metabolism, AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, GGT gamma-glutamyltransferase, LD lactate dehydrogenase, Hb hemoglobin